Srividya Kotapati
AstraZeneca (United States)(US)
Publications by Year
Research Areas
Cancer Immunotherapy and Biomarkers, Cutaneous Melanoma Detection and Management, CAR-T cell therapy research, Health Systems, Economic Evaluations, Quality of Life, Melanoma and MAPK Pathways
Most-Cited Works
- → Impact of Extended-Spectrum β -Lactamase–Producing Escherichia coli and Klebsiella Species on Clinical Outcomes and Hospital Costs: A Matched Cohort Study(2006)142 cited
- → Health-related quality of life with adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): secondary outcomes of a multinational, randomised, double-blind, phase 3 trial(2017)104 cited
- → Health-related quality of life results from the phase III CheckMate 067 study(2017)95 cited
- → Relapse-Free Survival as a Surrogate for Overall Survival in the Evaluation of Stage II–III Melanoma Adjuvant Therapy(2017)87 cited
- → Health related quality of life outcomes for unresectable stage III or IV melanoma patients receiving ipilimumab treatment(2012)62 cited
- → Ipilimumab in 2nd line treatment of patients with advanced melanoma: a cost-effectiveness analysis(2012)51 cited
- → The Ends Justify the Mean: Outcome Measures for Estimating the Value of New Cancer Therapies(2012)51 cited
- → Clinical and economic benefits of a meropenem dosage strategy based on pharmacodynamic concepts(2004)42 cited
- → Cost analysis of continuous versus intermittent infusion of piperacillin-tazobactam: a time-motion study(2003)39 cited
- → Clinical implications of extended spectrum β-lactamase (ESBL) producing Klebsiella species and Escherichia coli on cefepime effectiveness(2005)38 cited